BGT — Bio-Gene Technology Share Price
0.000.00%
Last trade - 00:00- AU$9.87m
- AU$6.64m
- AU$0.68m
- 43
- 14
- 14
- 11
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.4 | ||
| Price to Tang. Book | 2.55 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 11.64 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -70.83% | ||
| Return on Equity | -65.75% | ||
| Operating Margin | -346.17% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.64 | 1.04 | 0.64 | 0.93 | 0.68 | n/a | n/a | 7.49% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Bio-Gene Technology Limited is an Australia-based agriculture technology development company enabling the next generation of novel insecticides derived from nature to achieve high impact globally. Its technology is based on compounds with a novel mode of action proven to overcome insecticide resistance with minimal impact on human health and the environment. The Company’s technology provides multiple potential new solutions in applications across crop protection, grain storage, public health, and consumer products. It is developing and commercialising a broad portfolio of targeted insect control and pest management solutions. The Company's lead beta-triketone insecticide products include Flavocide and Qcide. Flavocide is a chemically synthesized product based on flavesone. Qcide is a natural oil product containing tasmanone as the active constituent. The Company operates in one business segment, being the conduct of research and development activities in the agricultural sector.
Directors
- Robert Klupacs CHM
- Richard Jagger CEO
- Roger McPherson CFO
- Peter Beetham NED
- Guthrie Guthrie NED
- James Joughin NED
- Peter May NED
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- November 8th, 1995
- Public Since
- November 29th, 2017
- No. of Shareholders
- 161
- Sector
- Chemicals
- Industry
- Basic Materials
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 201,361,570
- Address
- Melbourne, MELBOURNE, 3000
- Web
- https://bio-gene.com.au/
- Phone
- +61 396284178
- Auditors
- JTP Assurance
Upcoming Events for BGT
Bio-Gene Technology Ltd Annual Shareholders Meeting
Similar to BGT
Agrimin
Australian Stock Exchange - SEATS
Aguia Resources
Australian Stock Exchange - SEATS
Alexium International
Australian Stock Exchange - SEATS
Alpha HPA
Australian Stock Exchange - SEATS
Arcadium Lithium
Australian Stock Exchange - SEATS
FAQ
What is the Bio-Gene Technology share price?
As of Today at 19:37 UTC, shares in Bio-Gene Technology are trading at AU$0.04. This share price information is delayed by 15 minutes.
How has the Bio-Gene Technology share price performed this year?
Shares in Bio-Gene Technology last closed at AU$0.04 and the price had moved by -46.51% over the past 365 days. In terms of relative price strength the Bio-Gene Technology share price has underperformed the ASX All Ordinaries Index by -50.9% over the past year.
What are the analyst and broker recommendations for Bio-Gene Technology?
There is no consensus recommendation for this security.
What is the Bio-Gene Technology dividend yield?
Bio-Gene Technology does not currently pay a dividend.
Does Bio-Gene Technology pay a dividend?
Bio-Gene Technology does not currently pay a dividend.
When does Bio-Gene Technology next pay dividends?
Bio-Gene Technology does not currently pay a dividend.
How do I buy Bio-Gene Technology shares?
To buy shares in Bio-Gene Technology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Bio-Gene Technology?
As of the previous close price of AU$0.04, shares in Bio-Gene Technology had a market capitalisation of AU$8.86m.
Where are Bio-Gene Technology shares listed?
Here are the trading details for Bio-Gene Technology:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: BGT
What kind of share is Bio-Gene Technology?
Based on an overall assessment of its quality, value and momentum Bio-Gene Technology is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Bio-Gene Technology share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Bio-Gene Technology share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bio-Gene Technology. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -24.4%.
As of the last closing price of AU$0.04, shares in Bio-Gene Technology were trading -39.42% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Bio-Gene Technology PE Ratio?
The Bio-Gene Technology PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.04.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Bio-Gene Technology?
Bio-Gene Technology's management team is headed by:
- Robert Klupacs - CHM
- Richard Jagger - CEO
- Roger McPherson - CFO
- Peter Beetham - NED
- Guthrie Guthrie - NED
- James Joughin - NED
- Peter May - NED